Patent · US Active

Multiple exon skipping compositions for DMD

US9453225B2 · kind B2 · utility

23Cited by

85References

4Claims

0Family size

Assignee

Sarepta Therapeutics, Inc. · US

Inventors

Peter L. Sazani · Bothell, US
Ryszard Kole · Chapel Hill, US

Key dates

Filing date	Sep 17, 2015
Grant date	Sep 27, 2016
Priority date	—
Expiry date	Sep 17, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/33
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.